What is Vireo Growth Inc.'s (VREO.CN) StockRank?

MoatMap's StockRank for Vireo Growth Inc. (VREO.CN) is 28/100, with a Sell signal. This is a composite score combining Quality (44), Value (52), and Momentum (23) factor ranks across MoatMap's 20,000+ stock universe.

Does Vireo Growth Inc. have an economic moat?

Vireo Growth Inc. (VREO.CN) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Vireo Growth Inc. a buy, hold, or sell?

MoatMap's current signal for Vireo Growth Inc. (VREO.CN) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Vireo Growth Inc. in?

Vireo Growth Inc. (VREO.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VREO.CN

SELLREMOVE

Vireo Growth Inc. · Healthcare · United States · $532M · Avg Vol: $38K/d

StockRank

P/E (TTM)

—

ROE

-47.5%

D/E

1.4x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Vireo Growth is a cannabis operator. The sector is plagued by regulatory bottlenecks, lack of pricing power, and capital destruction, making it unsuitable for our quality-focused portfolio.

COMPANY DESCRIPTION

Vireo Growth Inc. is a physician-led cannabis company focused on scientific research and medical-grade product development. The company's competitive advantage is its strong intellectual property portfolio, which includes proprietary formulations and delivery systems, alongside operations in key limited-license states. Vireo operates as a vertically integrated multi-state operator, prioritizing science-based cannabis solutions for patients and consumers.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	52.7M	62.2M	70.1M	189.7M	53.3%
EPS	-1.53	-0.40	-0.85	-1.91	—
Shares	48.5M	48.5M	48.5M	36.0M	-25.7%
Debt	98.4M	57.0M	63.6M	214.3M	29.6%
Equity	2.4M	-11.3M	39.2M	217.0M	347.1%
Op CF	-12.8M	-0.7M	-7.2M	2.6M	—
Inv CF	-4.0M	-2.5M	-5.7M	6.2M	—
Fin CF	16.7M	3.7M	66.3M	13.0M	—

PRICE (1Y)+2537.0%

SMA 50SMA 200

$10.05

RSI (14)

24.5

52W High

$22.87

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-1.5%42.4

ROE

-47.5%18.6

GP/Assets

29.0%63.6

Op. Margin

16.7%77.7

FCF/Assets

11.1%89.6

Piotroski

549.0

Int. Cover

-0.3x35.9

D/E Ratio

1.37x10.2

Current Ratio

1.20x15.6

Value

P/E (TTM)

—N/A

EV/EBITDA

17.7x35.5

P/FCF

11.3x83.4

P/B

1.1x80.1

P/S

1.8x70.1

Div Yield

—N/A

Momentum

52W High %

44%21.6

RS 6M

-47%22.2

SMA 50/200

0.84x19.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$532M

P/E (Forward)

—

Gross Margin

49.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VREO.CN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
VREO.CN	Vireo Growth Inc.(you)	$532M	28	SELL
EOLS	Evolus, Inc.	$432M	32	SELL
ESPR	Esperion Therapeutics, Inc.	$814M	30	SELL
ORGO	Organogenesis Holdings Inc.	$309M	31	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL
TKNO	Alpha Teknova, Inc.	$272M	32	SELL
AQST	Aquestive Therapeutics, Inc.	$609M	11	STRONG SELL
AKBA	Akebia Therapeutics, Inc.	$299M	18	STRONG SELL
BIOA	BioAge Labs, Inc.	$959M	41	HOLD
HROW	Harrow, Inc.	$1.5B	32	SELL

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Vireo Growth Inc. (VREO.CN) — Stock Score Summary

Vireo Growth Inc. (VREO.CN) has a MoatMap StockRank of 28/100 based on Quality (44/100), Value (52/100), and Momentum (23/100) factor scores. The current signal is SELL. Vireo Growth is a cannabis operator. The sector is plagued by regulatory bottlenecks, lack of pricing power, and capital destruction, making it unsuitable for our quality-focused portfolio.

Key Financial Metrics

Price	$10.05
Market Cap	$532M
Price/Book	1.14
Return on Equity	-47.5%
Return on Invested Capital	-1.5%
Debt/Equity	137.27
Gross Margin	49.6%
Operating Margin	16.7%
Revenue Growth	333.5%
Free Cash Flow	$47M

Vireo Growth Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Vireo Growth Inc.’s (VREO.CN) StockRank?: MoatMap’s StockRank for Vireo Growth Inc. (VREO.CN) is 28/100, with a Sell signal. It is a composite of Quality (44), Value (52), and Momentum (23) factor ranks across MoatMap’s 20,000+ stock universe.
Does Vireo Growth Inc. have an economic moat?: Vireo Growth Inc. (VREO.CN) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vireo Growth Inc. a buy, hold, or sell?: MoatMap’s current signal for Vireo Growth Inc. (VREO.CN) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Vireo Growth Inc. in?: Vireo Growth Inc. (VREO.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).